Company intelligence / Profile preview

Yasheng Pharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Yasheng Pharmaceutical has over eight clinical drug candidates across cancer and other indications, including kinase inhibitors and apoptosis-targeting compounds; its clinical development has drawn global regulatory and academic recognition and includes multiple clinical trials up to Phase 3. The company received 12 FDA Orphan Drug designations, a record for a Chinese firm. HQP1351 received Breakthrough Therapy designation from China CDE for treating CML (Chronic Myeloid Leukemia).

Therapeutic areas: OncologyInfectious DiseasesRheumatology
Modalities: Small moleculeProteolysis-targeting chimera therapy (PROTAC)CAR-NK cell therapy
Industry: Biotech

Partnerships

National Cancer Institute (NCI), National Institutes of Health (NIH) (CRADA agreement for APG-1252)

Beyond the preview

Go deeper on Yasheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yasheng Pharmaceutical.

Explore the full profile